Summary
Noncoding mutations in cancer genomes are frequent but challenging to interpret.
PVT1 encodes an oncogenic lncRNA, but recurrent translocations and deletions in human cancers suggest alternative mechanisms. Here, we show that the
PVT1 promoter has a tumor-suppressor function that is independent of PVT1 lncRNA. CRISPR interference of
PVT1 promoter enhances breast cancer cell competition and growth
in vivo. The promoters of the
PVT1 and the
MYC oncogenes, located 55 kb apart on chromosome 8q24, compete for engagement with four intragenic enhancers in the
PVT1 locus, thereby allowing the
PVT1 promoter to regulate pause release of
MYC transcription.
PVT1 undergoes developmentally regulated monoallelic expression, and the
PVT1 promoter inhibits
MYC expression only from the same chromosome via promoter competition. Cancer genome sequencing identifies recurrent mutations encompassing the human
PVT1 promoter, and genome editing verified that
PVT1 promoter mutation promotes cancer cell growth. These results highlight regulatory sequences of lncRNA genes as potential disease-associated DNA elements.